/VRDN
VRDN Stock - Viridian Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$31.92+1.01%
+$0.32 (+1.01%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+30.2%upside
Target: $41.56
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VRDN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$31.60 – $32.24
TARGET (TP)$41.57
STOP LOSS$29.37
RISK/REWARD1:3.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.91
52W High$34.04
52W Low$9.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $302,000 | $314,000 | $1.77M | $2.96M | $1.05M |
| Gross Profit | $302,000 | $314,000 | $1.77M | $2.96M | $-27,254,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -2595.6% |
| Operating Income | $-299,035,000 | $-254,450,000 | $-134,304,000 | $-79,728,000 | $-110,380,000 |
| Net Income | $-269,949,000 | $-237,734,000 | $-129,874,000 | $-79,413,000 | $-110,715,000 |
| Net Margin | -89387.1% | -75711.5% | -7329.2% | -2680.2% | -10544.3% |
| EPS | $-3.98 | $-5.31 | $-3.91 | $-6.66 | $-31.20 |
Company Overview
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
17
85%
Hold / Neutral
3
15%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
17 Bullish3 Neutral/Bearish
Price Targets
$39
Average Target
↑ 22.5% Upside
Now
$20
Low
$39
Average
$51
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | Wedbush | Reiterated | Outperform | $47← $42 |
| December 3rd 2025 | William Blair | Initiation | Outperform | - |
| November 24th 2025 | Truist | Initiation | Buy | - |
| August 25th 2025 | Jefferies | Resumed | Buy | $44 |
| December 19th 2024 | Wells Fargo | Downgrade | Equal Weight | $27← $37 |
| November 25th 2024 | TD Cowen | Initiation | Buy | - |
| September 11th 2024 | Needham | Reiterated | Buy | $38← $30 |
| June 11th 2024 | Wolfe Research | Initiation | Outperform | $29 |
| June 6th 2024 | Goldman | Initiation | Buy | $23 |
| May 9th 2024 | Ladenburg Thalmann | Downgrade | Neutral | - |
| May 9th 2024 | B. Riley Securities | Downgrade | Neutral | $20← $25 |
| June 14th 2023 | Credit Suisse | Resumed | Outperform | $51 |
| June 14th 2023 | BTIG Research | Initiation | Buy | $46 |
| May 30th 2023 | RBC Capital Mkts | Initiation | Outperform | $44 |
| April 17th 2023 | Wells Fargo | Initiation | Overweight | $46 |
Earnings History & Surprises
VRDNBeat Rate
50%
Last 18 quarters
Avg Surprise
-22.1%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-0.34
Q4 2025
EPS Surprise History
Q4 23
+14.2%
$-1.09vs$-1.27
Q1 24
-35.0%
$-1.35vs$-1.00
Q2 24
+28.2%
$-0.79vs$-1.10
Q3 24
-14.6%
$-1.02vs$-0.89
Q4 24
-8.5%
$-1.15vs$-1.06
Q1 25
+22.9%
$-0.81vs$-1.05
Q2 25
+8.4%
$-0.87vs$-0.95
Q4 25
+58.5%
$-0.34vs$-0.82
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.88 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.82 | $-0.34 | +58.5% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.95 | $-0.87 | +8.4% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-1.05 | $-0.81 | +22.9% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-1.06 | $-1.15 | -8.5% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.89 | $-1.02 | -14.6% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-1.10 | $-0.79 | +28.2% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-1.00 | $-1.35 | -35.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-1.27 | $-1.09 | +14.2% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.29 | $-1.27 | +1.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-1.02 | $-1.61 | -57.8% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-0.73 | $-1.13 | -54.8% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-1.02 | $-0.86 | +15.7% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.90 | $-1.06 | -17.8% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.08 | $-0.98 | +9.3% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.85 | $-1.32 | -55.3% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-1.47 | $-1.25 | +15.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-1.52 | $-2.21 | -45.4% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-0.76 | $-2.91 | -282.9% | ✗ MISS |
Latest News
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $47
📈 PositiveBenzinga•Dec 10, 2025, 01:12 PM
William Blair Initiates Coverage On Viridian Therapeutics with Outperform Rating
📈 PositiveBenzinga•Dec 3, 2025, 02:31 PM
Truist Securities Initiates Coverage On Viridian Therapeutics with Buy Rating, Announces Price Target of $41
📈 PositiveBenzinga•Nov 24, 2025, 06:02 PM
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $45
📈 PositiveBenzinga•Nov 6, 2025, 04:30 PM
Viridian Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 5, 2025, 02:05 PM
Viridian Therapeutics Q3 EPS $(0.34) Beats $(0.98) Estimate, Sales $70.570K Beat $33.909K Estimate
📈 PositiveBenzinga•Nov 5, 2025, 12:25 PM
BTIG Reiterates Buy on Viridian Therapeutics, Maintains $61 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 10:20 AM
Viridian Therapeutics Submits BLA To FDA For Veligrotug, Investigational Therapy For Treatment Of Thyroid Eye Disease
📈 PositiveBenzinga•Nov 3, 2025, 12:11 PM
Reported Earlier, Viridian Therapeutics Prices $251.35M Public Offering Of 11.425M Common Shares At $22 Per Share, To Fund Veligrotug, VRDN-003 Commercial Launch, R&D Activities, And General Corporate Purposes
➖ NeutralBenzinga•Oct 22, 2025, 07:26 AM
Viridian Therapeutics Launches An Underwritten Public Offering Of Its Common Stock And Series B Non-Voting Convertible Preferred Stock; Financial Terms Not Disclosed
➖ NeutralBenzinga•Oct 21, 2025, 08:03 PM
DRI Healthcare Trust Acquires Royalty Interest In US Net Sales Of Veligrotug From Viridian Therapeutics For Aggregate Purchase Price Of $300M
📈 PositiveBenzinga•Oct 20, 2025, 11:34 AM
Frequently Asked Questions about VRDN
What is VRDN's current stock price?
Viridian Therapeutics, Inc. (VRDN) is currently trading at $31.92 per share. The stock has moved +1.01% today.
What is the analyst price target for VRDN?
The average analyst price target for VRDN is $41.57, based on 1 analyst.
What sector is Viridian Therapeutics, Inc. in?
Viridian Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VRDN's market cap?
Viridian Therapeutics, Inc. has a market capitalization of $2.59 billion, making it a mid-cap company.
Does VRDN pay dividends?
No, Viridian Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
Explore stocks similar to VRDN for comparison